Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2026

The attention deficit hyperactivity disorder (adhd) therapeutics market size has grown strongly in recent years. It will grow from $13.97 billion in 2025 to $14.67 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to increasing adhd diagnosis rates, growing awareness about mental health, availability of stimulant drugs, rise in pediatric adhd cases, development of early intervention programs.

The attention deficit hyperactivity disorder (adhd) therapeutics market size is expected to see strong growth in the next few years. It will grow to $17.86 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to advancement in precision medicine for adhd, adoption of digital therapeutics, expansion of telehealth platforms, integration of ai in adhd management, increasing adult adhd diagnosis. Major trends in the forecast period include personalized adhd treatment programs, telehealth and remote adhd management, digital therapeutics and mobile apps for adhd, non-pharmacological interventions growth, integration of behavioral and cognitive therapies.

The increasing prevalence of attention-deficit hyperactivity disorder is expected to drive the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market going forward. The rising prevalence of ADHD reflects the growing number of individuals diagnosed with this neurodevelopmental disorder over time. ADHD therapeutics target the multifaceted aspects of the condition, aiming to improve symptom management, functional outcomes, quality of life, and overall well-being for affected individuals. For instance, in May 2025, according to NHS England Digital, a UK-based national information and technology partner, an estimated 2,498,000 individuals in England are living with ADHD, including both diagnosed and undiagnosed cases. Therefore, the increasing prevalence of ADHD is driving the growth of the ADHD therapeutics market.

Major companies in the ADHD therapeutics market are focusing on developing digital innovations such as over-the-counter (OTC) versions of digital therapeutics to meet the rising demand for digital solutions and remote healthcare options. Digital therapeutics are evidence-based interventions delivered through high-quality software programs to prevent, manage, or treat medical conditions. These interventions can be used independently or alongside conventional medical treatments. For instance, in June 2023, Akili, a US-based digital health company, launched an OTC version of its video game-based digital therapeutic for adults with ADHD. The OTC product, EndeavorOTC, is designed to enhance attention, time management, and organizational skills. This launch follows the success of Akili's FDA-authorized prescription video game treatment, EndeavorRx, for children with ADHD, providing adults with a non-drug treatment option for managing symptoms.

In July 2024, Virtual Therapeutics Corp., a US-based digital health company, acquired Akili, Inc., for an undisclosed amount. Through this acquisition, Akili aims to integrate its validated mobile digital therapeutics with Virtual Therapeutics’ VR mental health solutions, creating a leading digital health company that delivers engaging, scalable games to improve mental health across multiple high-impact conditions. Akili, Inc. is a US-based digital therapeutics company specializing in ADHD therapeutics.

Major companies operating in the attention deficit hyperactivity disorder (adhd) therapeutics market are Pfizer Inc, Johnson & Johnson, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Otsuka Pharmaceutical Co Ltd, UCB S.A., Amneal Pharmaceuticals LLC, Lupin Limited, Mallinckrodt Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, Tris Pharma Inc, NEOS Therapeutic Inc, Rhodes Pharmaceuticals L.P., KemPharm Inc, Ironshore Pharmaceuticals Inc, Purdue Pharma L.P., Aevi Genomic Medicine, Highland Therapeutics Inc.

North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (adhd) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the attention deficit hyperactivity disorder (adhd) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the ADHD therapeutics market by increasing the cost of imported drugs, medical devices, and digital therapeutics components, particularly in regions like North America and Europe that rely on raw materials and active pharmaceutical ingredients from Asia. Stimulant drugs and non-stimulant formulations are the most impacted segments, with higher prices leading to tighter healthcare budgets. However, tariffs are encouraging local manufacturing and regional R&D investments, which may improve supply chain resilience and innovation in the long term.

The attention deficit hyperactivity disorder (adhd) therapeutics market research report is one of a series of new reports that provides attention deficit hyperactivity disorder (adhd) therapeutics market statistics, including attention deficit hyperactivity disorder (adhd) therapeutics industry global market size, regional shares, competitors with a attention deficit hyperactivity disorder (adhd) therapeutics market share, detailed attention deficit hyperactivity disorder (adhd) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder (adhd) therapeutics industry. This attention deficit hyperactivity disorder (adhd) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Attention deficit hyperactivity disorder (ADHD) therapeutics refers to the range of treatments and interventions designed to manage symptoms and enhance the functioning of individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder marked by inattention, hyperactivity, and impulsivity, which can significantly disrupt daily functioning and development. The main goal of ADHD therapeutics is to improve attention, impulse control, and overall performance in daily activities, thereby enhancing the quality of life for those affected by the disorder.

The primary types of drugs in ADHD therapeutics are stimulants and non-stimulants. Stimulants are medications that increase certain brain chemicals to help improve attention and focus. Treatments also include various psychotherapies, such as behavior therapy, cognitive behavioral therapy, interpersonal therapy, and family therapy. These interventions are tailored for different age groups, including pediatric, adolescent, and adult populations, and are distributed through hospital pharmacies, specialty clinics, retail pharmacies, and online platforms.

The attention deficit hyperactivity disorder (ADHD) therapeutic market consists of revenues earned by entities by providing services such as medication management, behavioral therapy, social skills training, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) therapeutic market also includes sales of medication, behavioral modification tools, organization and planning tools, and assistive technologies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.